普拉克索联合多巴丝肼治疗帕金森病的临床效果

扫码查看

原文链接

万方数据
维普

中文摘要：目的:分析普拉克索联合多巴丝肼治疗帕金森病(Parkinson disease，PD)的临床效果。方法:选取 2021 年9 月—2023 年 4 月三明市第一医院收治的 80 例PD病患者为研究对象，采用随机数表法将患者分为对照组(n=40)与观察组(n=40)，对照组实施多巴丝肼治疗，观察组实施普拉克索联合多巴丝肼治疗，两组患者均持续治疗 3 个月。比较两组患者治疗前、治疗 1 个月、治疗 3 个月非运动症状(non-motor symptom，NMS)、生活质量、运动功能，并统计患者治疗期间不良反应发生率。结果:治疗 1 个月、3 个月，观察组非运动症状问卷量表(non-motor symptom questionnaire，NMSQuest)评分、39 项帕金森生活质量问卷(39 item Parkinson disease quality of life questionnaire，PDQ-39)低于对照组，差异有统计学意义(P<0。05)。治疗 1 个月、3 个月，观察组各维度统一帕金森病评定量表(unified Parkinson disease rating scale，UPDRS)评分低于对照组，差异有统计学意义(P<0。05)。两组患者不良反应发生率比较，差异无统计学意义(P>0。05)。结论:相较于单独多巴丝肼治疗，普拉克索联合多巴丝肼治疗在PD患者中具有更好的效果，可显著改善NMS、生活质量和运动功能，且具备较高的安全性。

外文标题：Curative Effect of Pramipexole Combined with Levodopa and Benserazide Hydrochloride in Parkinson Disease Patients

外文摘要：Objective:To analyze the effect of Pramipexole combined with Levodopa and Benserazide Hydrochloride in patients with Parkinson disease(PD).Method:Eighty patients with Parkinson disease admitted to Sanming First Hospital from September 2021 to April 2023 were selected as the study subjects.The patients were randomly divided into control group(n=40)and observation group(n=40)by the random number table method.The control group received treatment with Levodopa and Benserazide Hydrochloride,while the observation group received treatment with Pramipexole combined with Levodopa and Benserazide Hydrochloride.Both groups of patients received continuous treatment for three months.The non-motor symptom(NMS),quality of life,motor function of the two groups before treatment,one month of treatment,and three months of treatment were compared,and the incidence of adverse reactions during treatment for patients was calculated.Result:After one month and three months of treatment,the scores of non-motor symptom questionnaire(NMSQuest)and 39 item Parkinson disease quality of life questionnaire(PDQ-39)in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After one month and three months of treatment,the unified Parkinson disease rating scale(UPDRS)scores in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no difference in the incidence of adverse reactions between the two groups of patients during treatment(P>0.05).Conclusion:Compared to Levodopa and Benserazide Hydrochloride individual treatment,Pramipexole combined with Levodopa and Benserazide Hydrochloride has better efficacy in PD patients,which can significantly improving non motor symptoms,quality of life,and motor function,and has higher safety.

外文关键词：

PramipexoleLevodopa and Benserazide HydrochlorideParkinson diseaseNon motor symptomsQuality of life

作者：

林蕾、杨东琴、许鲁宁

展开 >

作者单位：

三明市第一医院福建三明 365000

关键词：

普拉克索多巴丝肼帕金森病非运动症状生活质量

出版年：

2024

DOI：